We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

By LabMedica International staff writers
Posted on 18 Apr 2025

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. More...

Despite a substantial decline in deaths from previous years, AIDS-related deaths continue to represent a critical global health concern. While antiretroviral therapy (ART) has significantly increased life expectancy for people living with HIV, the lack of effective diagnostic tools and disease management strategies has hindered widespread implementation. Only 59% of those in need have access to ART, and approximately one in four individuals with HIV remain unaware of their status. Moreover, people on ART who maintain uninterrupted treatment might experience viral rebound between viral load tests, staying unaware of treatment failure and remaining potentially infectious for weeks or even months.

One of the key challenges in managing HIV is the absence of self-testing technologies capable of detecting new infections during the early acute phase (the first two weeks after infection) or identifying viral rebound in patients on ART. To date, no self-test has been developed to detect HIV during the acute phase or viral rebound in patients with suppressed viral loads on ART. In response to the pressing need for a rapid, affordable, and reliable self-test for early HIV detection, researchers at Florida Atlantic University (Boca Raton, FL, USA), in collaboration with other experts, are developing an innovative disposable microchip technology for HIV-1 self-testing. This technology would detect HIV within the first two weeks post-infection and monitor viral rebound in ART-suppressed patients. Additionally, the technology could be adapted for use in detecting other infectious diseases such as flaviviruses, hepatitis, tuberculosis, malaria, and SARS-CoV-2.

Unlike current HIV tests, which can be expensive, the new technology is expected to cost less than USD 5 per test. Present HIV testing methods, such as PCR-based assays, are costly, requiring expensive lab equipment, skilled technicians, and reagents, making them unsuitable for self-testing. Although miniaturized versions exist, they tend to be labor-intensive, and other tests are costly, require refrigeration, and have long turnaround times. Moreover, rapid tests that detect HIV antibodies are ineffective for early detection since antibodies typically appear three to four weeks after infection. Drawing on expertise in microchip fabrication, microfluidics, isothermal amplification, imaging, and microelectronics, the research team is working on an HIV-1 self-testing chip that can selectively detect HIV in whole blood samples.

The assay being developed will enable early detection of HIV during the acute infection phase or viral rebound, provide rapid results, and remain stable without the need for refrigeration. This handheld device will be battery-powered and fully automated, providing true "sample-in-answer-out" functionality with minimal user involvement. After loading the blood sample into the magnetic actuation platform, results will be available within 40 minutes, a substantial improvement over conventional assays that take several hours and require clinical lab infrastructure.

“Development of this novel self-testing technology is a game changer because it addresses a fundamental gap in HIV detection and management, particularly in impoverished areas where access to health care is limited,” said Stella Batalama, Ph.D., dean of the College of Engineering and Computer Science. “By developing an affordable, easy-to-use self-testing platform, we can empower individuals to detect HIV early, reduce transmission and improve treatment outcomes. This innovation has the potential to save countless lives, offering hope to those who otherwise might not have access to timely care, ultimately helping to curb the global HIV epidemic.”

Related Links:
Florida Atlantic University


New
Gold Member
Automatic Chemiluminescence Immunoassay Analyzer
Shine i2000
Portable Electronic Pipette
Mini 96
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
Urine Chemistry Control
Dropper Urine Chemistry Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: The collaboration aims to improve access to Hb variant testing with the Gazelle POC diagnostic platform (Photo courtesy of Hemex Health)

Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders

Millions of people worldwide living with sickle cell disease and other hemoglobin disorders experience delayed diagnosis and limited access to effective care, particularly in regions where testing is scarce.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.